KURA / Kura Oncology: Targeted AML Therapy Continues To Deliver

SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the more_horizontal

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive more_horizontal

Kura Oncology's lead candidate, ziftomenib, shows dual-functionality in treating NPM1-mutant AML and overcoming resistance mutations. Company's financ more_horizontal

Kura Oncology, Inc. (NASDAQ:KURA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice Preside more_horizontal

Kura Oncology, Inc. has additional updated results released from the KOMET-001 study, as part of an oral late-breaker presentation shown on June 11, 2 more_horizontal

Kura Oncology (KURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with s more_horizontal

Shares of Kura Oncology Inc. KURA, -1.24% dropped nearly 6% in the aftermarket Tuesday after the biotech said it plans to sell $100 million worth of s more_horizontal

Kura Oncology, Inc. (NASDAQ:KURA ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Pete De Spain - Senior Vice Pres more_horizontal